Individual human subject and study characteristics
. | . | . | . | Mean plasma [2H2]-glucose enrichment, %† . | Days evaluated* . | . | |
|---|---|---|---|---|---|---|---|
| Donor ID . | Sex . | Age, y . | Duration of infusion, h . | . | CD34+ cells . | CD133+ cells . | |
| D02 | M | 23 | 48 | 18.2 | 1, 14, 25 | ND | |
| D06 | M | 29 | 47 | 19.5 | 0, 14, 29 | ND | |
| D08 | F | 44 | 46 | 10.2 | 0, 14, 28 | ND | |
| D10 | F | 25 | 31 | 20.8 | 0, 14, 28 | ND | |
| D11 | M | 29 | 47 | 28.4 | 1, 14 | 28 | |
| D13 | F | 42 | 49 | 18.6 | 1, 15, 29 | 15, 29 | |
| D14 | F | 28 | 49 | 22.4 | 1, 15 | 1, 15 | |
| D15 | M | 19 | 48 | 29.6 | ND | 0, 14, 28 | |
| D16 | M | 27 | 47 | 18.1 | 0, 16, 29 | ND | |
| D18 | M | 26 | 48 | 31.8 | ND | 0, 14, 28 | |
| D19 | M | 84 | 45 | 50.4 | 14, 28 | ND | |
| D20 | F | 84 | 45 | 54.5 | 0, 14 | 14, 28 | |
| D21 | F | 21 | 48 | 40.6 | 0 | ND | |
| D22 | F | 24 | 45 | 29.3 | 0 | 0 | |
. | . | . | . | Mean plasma [2H2]-glucose enrichment, %† . | Days evaluated* . | . | |
|---|---|---|---|---|---|---|---|
| Donor ID . | Sex . | Age, y . | Duration of infusion, h . | . | CD34+ cells . | CD133+ cells . | |
| D02 | M | 23 | 48 | 18.2 | 1, 14, 25 | ND | |
| D06 | M | 29 | 47 | 19.5 | 0, 14, 29 | ND | |
| D08 | F | 44 | 46 | 10.2 | 0, 14, 28 | ND | |
| D10 | F | 25 | 31 | 20.8 | 0, 14, 28 | ND | |
| D11 | M | 29 | 47 | 28.4 | 1, 14 | 28 | |
| D13 | F | 42 | 49 | 18.6 | 1, 15, 29 | 15, 29 | |
| D14 | F | 28 | 49 | 22.4 | 1, 15 | 1, 15 | |
| D15 | M | 19 | 48 | 29.6 | ND | 0, 14, 28 | |
| D16 | M | 27 | 47 | 18.1 | 0, 16, 29 | ND | |
| D18 | M | 26 | 48 | 31.8 | ND | 0, 14, 28 | |
| D19 | M | 84 | 45 | 50.4 | 14, 28 | ND | |
| D20 | F | 84 | 45 | 54.5 | 0, 14 | 14, 28 | |
| D21 | F | 21 | 48 | 40.6 | 0 | ND | |
| D22 | F | 24 | 45 | 29.3 | 0 | 0 | |
ND indicates not determined.
Days after [2H2]-glucose infusion was discontinued that marrow aspirates were obtained and CD34+ and CD133+ cells were selected from those samples.
Mean plasma [2H2]-glucose enrichment was calculated from measurements in plasma samples obtained at 12, 24, and 48 hours from the start of the [2H2]-glucose infusion period.